Based on these research findings, the NCCN Clinical Practice Guidelines for Breast Cancer 2025, Version 2, recommend alpelisib in combination with fulvestrant as the preferred second‐line treatment (Class 1) for postmenopausal breast cancer patients with HR‐positive/HER2‐negative PIK3CA mutations [45]. Here, ERBB2 is linked to breast cancer.